- On track to file for marketing approval of hormonal contraceptive Myring™ in EU and US in Q2 2017
- Approval ensures Mithra fully prepared to ship first commercial batches in Europe
Liege, Belgium 23 May 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce that the Mithra CDMO has received Good Manufacturing Practice (GMP) approval for the production line of Myring™, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA).